We have analysed serum samples taken from hepatitis B virus (HBV) e antigen (HBeAg)-positive and HBeAgnegative chronic active hepatitis (CAH) patients by PCR using primers spanning the pre-core/core (C) and pre-S1/$20RFs. Nucleotide sequence analysis showed that among 18 HBV-infected CAH patients, 11 had virus with a G to A mutation (nucleotide 1896; leading to the formation of a stop codon) and one patient also had virus with an additional G to A mutation three nucleotides downstream (nucleotide 1899). HBV from three patients that were HBeAg-negative showed a 1 bp deletion at nucleotide 1937, causing pre-termination of the C gene. Mutation frequencies in the sequences identified as coding for cytotoxic T lymphocyte epitopes, B cell epitopes, CD4 ÷ helper T cell epitopes and arginine-rich regions of the HBV C peptide were investigated. Mutations were more frequently identified in these regions, suggesting that the mutations might have been selected as a result of immune responses.
Introduction
In chronic hepatitis B, disease is usually associated with continuous virus replication and release of hepatitis B virus (HBV) e antigen (HBeAg) into patients' serum (Hoofnagle et al., 1981 ; Realdi et al., 1980) . The inactive phase of hepatitis B is characterized by normal transaminase concentrations and the occurrence of antiHBeAg antibodies in serum, coupled with the absence of virus replication (Hoofnagle et al., 1987) . These patterns of chronic hepatitis B infections are found in the vast majority of individuals with the wild-type virus. Recently, a subgroup of patients was described with a severe form of chronic active hepatitis (CAH). These patients had HBV DNA in their serum, indicating virus replication despite the presence of anti-HBeAg antibodies (Hadziyannis et al., 1983) . Molecular analysis of the virus genome showed changes in the nucleotide sequence of the pre-core (C) region and provided strong evidence of HBeAg-defective HBV mutants in HBVpositive chronic hepatitis. In most of these cases there was an in-frame TAG stop codon in the distal pre-C region, which was shown to be related to the absence of HBeAg secretion; the distal pre-C region is a signal sequence essential for HBeAg synthesis and secretion * Author for correspondence. Fax +82 42 860 4593. (Omata et al., 1990; Tong et al., 1990) . In addition, other mutations (start codon, frame-shifts, coding changes and silent mutations) in the pre-C region have been found in carriers of this HBV subgroup from all over the world (Yurkaspa et at., 1992; Ou et al., 1986) . These variants emerge-spontaneously during seroconversion from HBeAg to anti-HBeAg Raimondo et at., 1990) and are also reported to emerge during interferon (Santantonio et al., 1991; Takeda et al., 1990) and vaccine treatment (Carman et aI., 1994) . Some chronic HBV carriers are infected with a mixture of wild-type and pre-C mutant viruses and during episodes of the disease the wild-type is sometimes selectively eliminated, which can prolong virus persistence .
HBV core antigen (HBcAg) has been postulated to be an immunological target for cytotoxic T lymphocytes (CTLs) (Penna et al., 1987; Milich et al., 1989; Vento et al., 1985) . Selective pressure from CTLs may result in substitutions in the amino acids in a restricted segment of the core protein containing the CTL epitope (Rotzschke & Falk, 1991) . It has been demonstrated that a cluster of mutations in a region of the C gene (codons 84-101) were related to liver damage in patients with chronic HBV infections (Ehata et al., 1992) . Vaccine-induced escape mutants have been identified (Carman et al., 1994) ; immunized infants who were HBV surface antigen (HBsAg)-positive were considered to have an escape mutant with different sequences from that of the isolate from their mother (Carman et al., 1994) .
0001-3710 © 1996 SGM In this report, we analysed nucleotide and amino acid sequences of the pre-C/C and pre-S1/S2 region of the HBV genome from CAH patients by PCR and direct sequencing methods. We found high-frequency mutation regions in the pre-C/C ORF; these regions in the resulting protein might be targets for CTLs, B lymphocytes and CD4 + T cells. We also investigated the mutation frequencies of the arginine-rich regions in the HBV core protein. Studies of the escape mutants in these regions may help to predict the outcome of HBV-related liver diseases.
Methods
Patients. Sera from 18 patients with CAH were used (Table 1) . Liver biopsies showed CAH in all samples. All patients were tested for HBsAg, HBeAg and anti-HBeAg antibodies using an RIA kit (Abbott Laboratories). The presence of HBV DNA was determined by dot blot hybridization using a HBV DNA fragment as probe. All patients were seropositive for HBV DNA and had varied alanine aminotransferase (ALT) levels (Table 1 ). All samples were negative for anti-hepatitis C virus antibody (assayed using Abbott HCV ELISA second generation kit).
HBV DNA purification. Isolation of HBV DNA from serum was performed as described by Kaneko & Miller (1989) . Briefly, a sample Pre-core/core region
' . ~t'ys~lMha;ly.¢l~ hll~O/al hsghT~t~l~-r'hcQ~lT~lI~,glhfra~lyT~ ta~l[e ~-1~ 1 u~Tk~/a lhl Argyll y ~¢g~Cg~Sa~;l ~t'r~ Amplification of the pre-C/C and pre-Sl/S20RFs of HBV DNA by PCR. To amplify the pre-C/C ORF (positions 1814~2452; 639 bp) and the pre-S1/S20RF (2848-156; 522 bp) of HBV, synthetic primers were prepared according to the reported sequence of the HBV adr subtype (Chisari et al., 1989) (Fig. 1 ). Using these primers, segments of HBV DNA spanning the entire pre-C/C and pre-S1/S2 regions were amplified. The primers were synthesized by the phosphoramidite method. Amplification of HBV DNA was performed basically by the method described previously (Omata et al., 1990) . Briefly, 100 ktl reaction mixtures containing 1 ktl of the serum DNA sample, 50 mM-KC1, 10 mM-Tris-HC1 pH 8.4, 2-5 mM-MgC12, 1 mM each of the two oligonucleotide primers, 200 taM-dNTP and 2 units of Taq DNA polymerase were overlaid with 100 lal of mineral oil. Samples were heated at 95 °C for 2 min (denaturation), cooled to 50 °C for 2 rain (annealing) and heated to 70 °C for 2 min (extension). These steps were repeated for 33 cycles in a programmable DNA thermal cycler (Hybaid). For each sample, an aliquot of the amplified DNA was fractionated with 2 % NuSieve agarose (FMC Bioproducts), separated by electrophoresis and visualized by UV fluorescence after staining with 0.05 % ethidium bromide.
Subcloning and sequencbzg of amplified HBV DNA. We inserted an amplified DNA, spanning the pre-C/C and pre-S 1/$20RFs, by bluntend ligation into Sinai-digested plasmid pUC19 (Promega), using the cloning procedures described (Chisari et al., 1989) . The recombinant plasmids were introduced in Escherichia eoli DH5ct (BRL) and cloned. To sequence the amplified segment bidirectionally, we prepared several sequencing primers (Fig. 1) . Three to four clones of each amplified product were sequenced by dideoxynucleotide chain termination (Sanger et al., 1977) using Sequenase version 2.0 (USB). The reliability of the sequencing results was ensured by analysing clones from an independent amplification experiment. Sequencing products were separated on 6 % acrylamide-urea gels. Nucleotide sequence mutations in known B cell epitopes (amino acids 74~89, 130-138 and 107-118), CD4 + helper T cell epitopes (amino acids 1-20, 50-69 and 117-131; Nayersina et al., 1993 ; Bertoletti et al., 1991) and HLA-restricted CTL epitopes (18 27 and 141 151) of the core region were determined and analysed Nassal et al., 1992) . Besides these, the nucleotide sequence of the arginine-rich C-terminal region of the core, which is important for pregenomic RNA encapsidation (amino acids 150-154) and HBV DNA synthesis (158-171), was determined and analysed (Nassal & Rieger, 1993) .
Results

Clonal analysis of the pre-C/C ORF
A number of naturally occurring HBV mutants were identified in patients with CAH. Four different groups of patients were identified (Table 1) . Group A showed an elevated ALT level and were HBeAg-positive, antiHBeAg-negative and HBV DNA-positive with CAH histology. Group B showed a normal ALT level but had the same immunological markers as group A. Group C were HBeAg-negative and anti-HBeAg-positive with CAH histology. In group C all HBV pre-C/C ORFs had a G to A mutation at position 1896, thus creating a termination codon (TAG). Group D were HBeAgnegative and anti-HBeAg-positive with a low level ALT and CAH histology. In group D, all HBV sequences except that from patient D 1 included a point deletion in the C gene region resulting in a stop codon (TAG).
All mutations and deletions in the pre-C/C nucleotide sequences of the obtained clones are shown in Fig. 2 in comparison to the wild-type sequence. In sample A5, a 9 bp deletion (positions 69-77) in the middle of the C gene was identified. Since the deletion was a multiple of three nucleotides it did not cause a frame-shift and the variant could therefore be translated through to the end of the C gene. Viruses which had a stop codon in the pre-C sequence could also be isolated from HBeAg-positive patients. These results confirm our previous findings that there were gradual changes in the HBV pre-C/C ORF in individual CAH patients (Hur et al., 1996) , which would explain the possible existence of mixed populations of mutants and wild-type viruses.
All patients showed various point mutations in the pre-C/C ORF. Among 18 patients, 14 had a stop codon in the pre-C or C regions. Eleven clones showed a point mutation from G to A at nucleotide 1896 of the pre-C region, converting TGG (tryptophan) to a stop codon (TAG). Four patients (D1, 2, 3 and 4) had a deletion mutation in the C region (nucleotide 1937), which caused a frame-shift and resulted in a premature stop codon (TAG) in the C region. Fig. 3 shows the data for four different cases of nonsense mutations of the pre-C/C region which were found in the 18 CAH patients. Fig. 3 (a, ii) shows a pre-C sequence with a 1 bp mutation at position 1896, resulting in a stop codon instead of tryptophan. Fig. 3 (a, iii) shows a double mutation at 1896 and 1899, resulting in a stop codon (TAG) and a GGC (glycine) to GGA (aspartic acid) change in the pre-C region. Fig. 3 (b, iii) shows a C sequence with a 1 bp deletion at nucleotide 1937, resulting in a premature stop codon. Fig. 3 (b, ii) shows a G to A mutation at nucleotide 1896 and a 1 bp deletion at position 1937, resulting in a premature stop codon in the middle of the C region.
Clonal analysis of the pre-S1/S2 0RF
Mutations and deletions in the pre-S1/S2 nucleotide sequence of the isolated clones compared to the HBV adr subtype are illustrated in Fig. 4 . In the pre-S1 region, four deleted HBV clones were observed. All of these mutations were at the initiation codon; nucleotide A in patient C2 and C5 clones and T in A2 and patient D4 clones. These mutant viruses, with deleted pre-S1 initiation codons, may use another initiation codon (ATG) 33 bp downstream from the original. Beside deletions, there were numerous missense mutations in the pre-S 1 region of the isolated clones. As shown in Fig.  4 , there was a small region in the middle of pre-S1 with a high frequency of missense mutations (amino acids 
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1133 78-90). In the pre-S2 region, three clones showed deletion mutations, two of which had the same 30 bp deletion (C1, D2) and one (A2) showed a 27 bp deletion. Since the size of the pre-S2 deletions were in multiples of three nucleotides, they did not cause frame-shift alterations, as in the C region mutation in patient A5, and these inframe variants could be translated through to the end of the pre-S2 gene.
Comparison of deduced amino acid sequences of pre-C/C and pre-S1/S2 peptides
The deduced amino acid sequences of pre-C, C, pre-S1 and pre-S2 peptides from 18 patients with C A H were aligned as shown in Fig. 5 . Among 18 samples, tl peptides resulted from an early termination codon in the pre-C region, while four had an early termination codon in the C region, caused by a 1 bp deletion (Fig. 5a ), In order to assess the significance of the mutations in the C region, their distribution was studied ( Table 2 ). As shown in Fig. 5 (b) , pre-S1/S2 peptide mutations in 18 C A H patients were not as dramatic as those of the pre-C / C region. There were several deletions in the Nterminal region of pre-S1 and the middle region of the pre-S2 peptide; since these deletions were found in multiples of 3 bp as previously discussed, the deletions did not affect the translation of the mutant pre-S1/S2 peptides.
Distribution of mutations in the C gene
The distribution of mutant amino acids was determined from the known sequences of B cell epitopes, CD4 + epitopes, CTL epitopes and arginine-rich regions of the HBV core protein (Table 2) . In general, patients that were seroconverted to HBeAg-negative had significantly more amino acid changes than patients that remained unchanged (HBeAg-positive) (Table 2) . However, the number of nucleotide changes was similar (Fig. 2) . The amino acid mutations were not evenly distributed throughout the C protein ( Fig. 5a; Fig. 6 ). Of the B cell epitopes (Table 2 ; Fig. 6 ), the HBe2 determinant (amino acids 130-138) had 10 amino acid changes in the 18 patients, with five changes at codon 13 and five at codon 135 (proline to threonine and serine, respectively). Six A2  A3  A4  A5  B1  C1  C2  C3  C4  C5  C6  C7  DI  D2  D3  D4  D5 amino acid changes were detected in the H B c / e / determinant (positions 74-89). Of these, five were at codon 88 (all were serine to glycine). The B cell epitope at positions 107 to 118 was highly conserved with two amino acid changes in two patients only.
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Among the CD4 + helper T cell epitopes, that at codons 1 to 20 had the highest frequency of amino acid changes (Table 2; Fig. 6 ). Eleven amino acid changes were found in four codons in the 18 patients. Nine changes were found in four codons in the epitope at 50-69 (seven of the changes involved isoleucine to phenylalanine or threonine). The epitope at codons 167 to 131 was more conserved. In the two CTL epitopes, the HLA A2.1-restricted epitope (18-27) was well conserved: only two amino acids were changed (Table 2; Fig. 6 ). But in the HLA A31/Aw68-restricted epitope (141-151), seven amino acid changes were found, of which six were valine to isoleucine. Five patients (6.25%) had amino acid changes in the C-terminal arginine-rich region that is important for D N A binding (amino acids 155-171). Four changes involved the arginine residues. Surprisingly, there was a very high rate of amino acid changes in the arginine-rich region that is involved in RNA-binding (amino acids 150-154). Among ten patients, two had changes that involved the arginine residue at codon 152, to cysteine and glutamine. Six had A1  WT  A2  M1  A3  M1  A4  WT  A5  WT   B1  M1   C1  M1  C2  M1  C3  M1  C4  M1  C5  M1  C6  M1  C7  M1   D1  WT  D2  WT  D3  WT  D4  WT  D5 WT valine to isoleucine changes and the other two had glycine to lysine changes.
Discussion
In the study, we examined the frequency and nature of naturally occurring HBV pre-C, C, pre-S1 and pre-S2 gene mutations in 18 patients with CAH. We confirmed our previous results in which mutations in the C gene can be frequently detected in patients with CAH and these mutations are more often found in HBeAg-negative patients with active liver disease (Hur et al., 1996) . These data and our previous results also confirmed that the mutations occur more frequently at the time of seroconversion when liver disease is more likely to be active. We realized that our technique, PCR and direct sequencing, enabled us to determine only the predominant HBV sequence; minor HBV sequences with other mutations may be missed. However, in our opinion it is impractical to sequence multiple minor clones from such a large population of patients. We also noticed that differences from the published prototype HBV sequence did not necessarily represent mutations that occurred within the patients. However, the high degree of similarity between amino acid sequences from patients in the early phase of infection and the published prototype sequence suggests that most of the amino acid changes emerged or were selected for during the course of infection. Our previous (Hur et al., 1996) and present data, along with the findings of others (Ehata et al., 1992) , suggest that mutations in the C gene can be frequently detected in chronic HBV infection and these mutations were more often found in HBeAg-negative patients and in patients with active liver disease.
Chronic hepatitis patients who have been exposed to HBV antigens in their early years tend to have mild or inactive liver disease during the initial phase of HBV infection, despite high levels of virus replication. This is thought to be due to immune tolerance as a result of early exposure to HBV antigens. It is generally acknowledged that HBV is not directly cytopathic for the infected hepatocyte. The cellular immune responses to HBV-encoded antigen may be responsible for HBVinduced liver disease and probably play an important role in virus clearance as well.
Liver disease becomes active in patients between the ages of 20 and 40, when the level of HBV replication declines and seroconversion of HBeAg to anti-HBeAg occurs. This transition from a mild or inactive disease state to an active one may be caused by the breakdown in immune tolerance with age. After the immune system becomes activated, virus mutations that can evade immune recognition may be induced or selected.
Class I MHC-restricted CTLs have been demonstrated to have potent antiviral activity both in vitro and in vivo.
Viruses have evolved some mechanisms for avoiding the CTL responses. Escape from host CTL might play a role in the ability of viruses to maintain persistent and lifelong infections. Several lines of evidence suggest that CTLs are an important component of the protective immune response to virus infection. During the prolonged asymptomatic phase of infection, virus antigenspecific CD8 + MHC I-restricted CTL activity can be routinely detected in the absence of stimulation.
However, despite the vigorous CTL response, the virus continues to replicate. Progression to viral diseases is marked by an increase in virus replication accompanied by a loss of the CD8 ÷ virus-specific CTL response. One simple explanation of the escape of persistent virus from the CTL response is that the virus simply develops altered amino acid sequences within the epitopes recognized by the CTLs. There is much evidence of virus escape from the host CTL reactions through mutations in the amino acid sequences of CTL-targeted epitopes. But several other ways of avoiding the response have been proposed (Koup, 1994) . Variations in regions surrounding a CTL epitope have been shown to lead to non-recognition by influenza virus-specific CTLs (Eisenlohr et al., 1992) . In addition, lymphocytic choriomeningitis virus has been shown to alter sequences within defined epitopes as a mechanism of escape both in vitro and in vitro. In Epstein-Barr virus sequences, alterations of key amino acid residues critical for the binding of the peptide epitope to the HLA A11 molecule have been identified (de Campos-Lima et al., 1994) . These sequence variations in many different virus systems against the host CTL response can be explained as natural selection of the variant viruses against adverse host immune systems; the viruses that escape from the host immune detection survive and cause persistent infections in the host.
HBcAg has been known to be an important target for CTL attack. Recent studies on the C gene revealed that frequent mutations occur during CAH or fulminant hepatitis. These mutations may change the immune recognition sites of HBcAg, thereby eliciting or evading immune clearance of the virus.
In all HLA A2-positive patients with acute HBV infection, residues between 18 and 27 of the HBcAg have been identified to contain an epitope that is recognized by CTLs. Also, HLA A31/Aw68-restricted CTL epitopes in the HBV core (141-151) have been identified (Bertoletti et al., 1993; Hatton et al., 1992) .
Immunodominant CD4 + T cell epitopes (1-20, 50-69, 117-131) and HBc/e/ B cell determinants (74-89, 107-118, 130-138) on the HBcAg have been identified . Besides these, an arginine-rich region located at the C terminus of the core has been identified as important for DNA-binding and RNA-binding. We determined mutation frequencies in four different epitope regions in the HBcAg isolated from 18 CAll patients.
Analysis of the rate of mutation in previously identified immune recognition sites showed a high level in some helper B cell and T cell epitopes. Among three different B cell epitopes (Fig. 6 ) so far identified, one (amino acids 107-118) showed relatively conserved amino acid sequences, while the other two showed a high rate of mutation. One CTL epitope (amino acids 18-27) had relatively conserved amino acid sequences while another (141-151) showed a high rate of mutation. The conserved amino acid sequences in CTL epitopes may be related to the fact that their recognition is HLA-restricted. Since we do not have data on the HLA haplotypes of the infected patients, we could not determine whether the mutations in the CTL epitopes were confined to patients with appropriate HLA alleles. Cysteine residues have been found to be important for the secretion of monomeric HBeAg and the assembly of HBcAg. Among six cysteine residues coded for by the pre-C/C gene, only one was changed. However, three patients had additional cysteines at codons 18, 149 and 152. These new cysteines may participate in the formation of additional disulphide bridges, thereby altering the secondary/tertiary structure of the core protein and the assembly of core particles. Unexpectedly, in the C-terminal region, known to be important for DNA-and RNA-binding, the mutation rate was very high, especially in the arginine-rich region (amino acids 151--155) that is important for RNAbinding. Two of the three CD4 + T cell epitopes showed a very high rate of mutation (13"75% and 11"25%). Although the biological significance of most of these mutations remains uncertain, amino acid changes in B cell epitopes can abolish antibody-binding, as in the case of a vaccine-induced mutant with the 'a' determinant (amino acids 124-147) mutation of HBsAg.
In this study, mutations in the pre-C/C and pre-S1/S2 ORFs were frequently found in patients with HBV CAH. During immune tolerance phases, the mutation rates were low, but from the beginning of immune clearance, mutation rates became high. The accumulation of mutations was identified as non-random since identical mutational changes were identified in many different patients infected with HBV and in single patients with mixed HBV variant infections. Our results showed that mutations were more frequently detected around immune recognition sites, suggesting that mutations might have been selected as a result of immune pressure.
